|
| | Albiglutide Basic information |
| Product Name: | Albiglutide | | Synonyms: | albiglutide;Albugon;Naliglutide;7-36-Glucagon-like peptide I (8-glycine) (human), fusion protein with 7-36-glucagon-like peptide I (8-glycine) (human) fusion protein with serum;Gsk 716155;Unii-5E7U48495e;7-36-Glucagon-likepeptide I [8-glycine] (huMan), fusion protein with 7-36-glucagon-like peptide I[8-glycine] (huMan) fusion protein with seruM albuMin (huMan);Albiglutide Fragment | | CAS: | 782500-75-8 | | MF: | C148H223N39O46 | | MW: | 3284.58792 | | EINECS: | | | Product Categories: | GLP | | Mol File: | 782500-75-8.mol |  |
| | Albiglutide Chemical Properties |
| storage temp. | Store at -20°C | | Water Solubility | Water: 100 mg/mL (30.45 mM); |
| | Albiglutide Usage And Synthesis |
| General Description | Albiglutide (also known as naliglutide, GSK 716155) isa sequential dimer of GLP-1(7–36)(Ala8→Gly) covalentlylinked to modified human serum albumin (i.e., it is a “fusionprotein” with modified HSA). This molecule is currentlywell into phase III clinical trials. Although albiglutide,if marketed (Syncria, GlaxoSmithKline), will—likeexenatide—be administered by injection, the half-life andduration of 6 to 7 days would allow for weekly administration. | | Clinical Use | GLP-1 receptor agonist:
Treatment of type 2 diabetes mellitus | | Enzyme inhibitor | This GLP-1 agonist and anti-diabetic drug (MW = 72.9 kDa; CAS 782500- 75-8), marketed as Eperzan? and Tanzeum?, by GlaxoSmithKline (GSK) is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide has a half-life of 4-7 days, commending it for biweekly or weekly administration in the treatment of Type 2 diabetes. The half-life is considerably longer than exenatide (Byetta?) and liraglutide (Victoza?). | | Metabolism | Albiglutide is a protein for which the expected metabolic
pathway is degradation to small peptides and individual
amino acids by ubiquitous proteolytic enzymes. |
| | Albiglutide Preparation Products And Raw materials |
|
